FMC Corporation reported third‑quarter 2025 financial results, showing revenue of $542 million, a 49% decline year‑over‑year. The drop was largely driven by a $510 million write‑down of its India commercial business, which was valued at $960 million and written down to an estimated fair value of $450 million as part of a divestiture process.
Adjusted earnings per share were $0.89, surpassing consensus estimates of $0.84. GAAP net loss stood at $4.52 per share. Adjusted EBITDA reached $236 million, up 17% from the same period a year earlier, supported by cost‑saving initiatives and a 2% increase in overall volume, largely from the growth portfolio.
The company revised its full‑year outlook downward, projecting revenue of $3.92 billion to $4.02 billion, adjusted EBITDA of $830 million to $870 million, and adjusted EPS of $2.92 to $3.14. The guidance cuts reflect pricing pressure from generic competition in Latin America and Asia, and the impact of the India divestiture.
FMC also reduced its quarterly dividend to $0.08 per share to prioritize debt reduction and cash generation. Management noted that while the core portfolio faced lower volume due to competition for non‑diamide legacy products, the growth portfolio saw mid‑single‑digit volume increases and new active ingredients nearly doubled in the quarter.
CEO Pierre Brondeau said the results reflect challenges in Latin America but highlighted the continued focus on new active ingredients and the ongoing sale process of the India commercial business, expected to conclude within the next year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.